GMAB - Genmab AS - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

GMAB is currently covered by 8 analysts with an average price target of $28.46. This is a potential upside of $7.96 (38.83%) from yesterday's end of day stock price of $20.5.

Genmab AS's activity chart (see below) currently has 80 price targets and 117 ratings on display. The stock rating distribution of GMAB is 82.69% BUY, 9.62% SELL and 7.69% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 23.54% with an average time for these price targets to be met of 51.63 days.

Highest price target for GMAB is $48, Lowest price target is $27, average price target is $37.86.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 09-Apr-2025.

Currently out of the existing stock ratings of GMAB, 43 are a BUY (82.69%), 5 are a SELL (9.62%), 4 are a HOLD (7.69%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$37

$16.5 (80.49%)

$50

2 months 19 days ago
(09-Apr-2025)

9/47 (19.15%)

$18.17 (96.49%)

131

Buy

$45

$24.5 (119.51%)

$50

3 months 17 days ago
(11-Mar-2025)

6/14 (42.86%)

$24.74 (122.11%)

87

Buy

$27

$6.5 (31.71%)

$31

4 months 15 days ago
(13-Feb-2025)

4/5 (80%)

$6.08 (29.06%)

173

Buy

$48

$27.5 (134.15%)

$48

7 months 21 days ago
(07-Nov-2024)

1/3 (33.33%)

$24.89 (107.70%)

26

Hold

$31

$10.5 (51.22%)

$31

9 months 17 days ago
(11-Sep-2024)

0/2 (0%)

$4.07 (15.11%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GMAB (Genmab AS) average time for price targets to be met?

On average it took 51.63 days on average for the stock forecasts to be realized with a an average price target met ratio 23.54

Which analyst has the current highest performing score on GMAB (Genmab AS) with a proven track record?

MATTHEW HARRISON

Which analyst has the most public recommendations on GMAB (Genmab AS)?

Matthew Harrison works at MORGAN STANLEY and has 7 price targets and 8 ratings on GMAB

Which analyst is the currently most bullish on GMAB (Genmab AS)?

Etzer Darout with highest potential upside - $27.5

Which analyst is the currently most reserved on GMAB (Genmab AS)?

Matthew Harrison with lowest potential downside - -$0

Genmab AS in the News

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives

Total Revenue Growth: 19% increase, driven by strong performance of Abkindi and TIFA. Operating Profit Growth: 62% increase in operating profits. Cash Position: Over $3 billion in cash at the end of the quarter. Share Buyback: Initiated a planned buyback of up to 2.2 million shares. Recurring Revenue Growth: 33% increase, with royalties from Darzalex...

Genmab Announces Financial Results for the First Quarter of 2024

Genmab A/S May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL) Rinatabart sesutecan (Rina-S®) continues to show encouraging antitumor activity in patients...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?